A 22-year-old entrepreneur named Peeyush Shrivastava and colleagues have created a new 3D heart-scanning technology, Faraday, which he hopes will one day be known as the “ER standard for ruling out cardiac versus non-cardiac chest pain.” Shrivastava’s biotech company, Genetesis, has millions of dollars in backing from the likes of billionaire Mark Cuban.
Faraday, according to Shrivastava, can reduce the time to diagnose whether chest pain is heart-related. It uses artificial intelligence (AI) to create thousands of 3D maps of a patient’s heart to tell physicians the source of what is causing heart pain.
Noninvasive sensors are placed above the chest to produce magnetic data. A system of algorithms analyzes the data into 3D maps that can pinpoint a cardiac-related problem including lack of blood flow—all within 90 seconds.
At present, the technology is being tested at St. John’s Hospital and Medical Center in Detroit and Genetesis is finishing its application for FDA approval.
To read the story in its entirety, click the link below:
As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.